Recently, the 2025 inter-laboratory quality assessment (EQA) results for metagenomic next-generation sequencing (mNGS) of pathogenic microorganisms, organized by the Guangdong Clinical Laboratory Center, were officially released. YunKang Group · Guangzhou DaAn Clinical Laboratory, with stable and outstanding performance, passed the evaluation in all three core testing modules – blood, lower respiratory tract, and central nervous system infections – with excellent results. This marks the establishment of stable and accurate multi-scenario mNGS testing capabilities for YunKang.

Blood cfDNA mNGS Testing

This assessment was highly challenging, evaluating the detection of bacteria, fungi, DNA viruses, and RNA viruses, including Mycobacterium tuberculosis, Candida albicans, adenovirus, hepatitis B virus, and human herpesvirus type 5. It demanded extremely high sensitivity and accuracy from the testing system.

Lower Respiratory Tract Infection mNGS Testing

The respiratory tract harbors a complex and vast microbial community. YunKang’s mNGS testing demonstrated excellent broad-spectrum detection capability and accurate discrimination between colonization and infection in the simultaneous identification of bacteria, viruses, fungi, and atypical pathogens.

Central Nervous System Infection mNGS Testing

In CNS infection testing, even with precious, low-volume specimens such as cerebrospinal fluid, YunKang’s mNGS achieved highly sensitive capture and precise identification of pathogens. This provides a solid technical foundation for rapid pathogen diagnosis of critical CNS infections, including viral encephalitis, bacterial meningitis, and fungal CNS infections.

As the “fiery golden eyes” for diagnosing difficult and critical infectious diseases, YunKang’s mNGS technology continues to lead the field, stemming from its years of extreme pursuit in technology development and quality control. The group’s “YunZhiYuan – Metagenomic Next-Generation Sequencing (mNGS) for Pathogens” project has established a detection system covering over 26,000 pathogen species, simultaneously capturing drug resistance gene information to provide direct evidence for precise clinical medication.

Meanwhile, YunKang has successfully passed mNGS inter-laboratory quality assessments organized by authoritative institutions such as the National Center for Clinical Laboratories and the Shanghai Center for Clinical Laboratory for many consecutive years, demonstrating long standing technical stability and reliability validated by the industry. Behind this achievement lies the strong support of YunKang’s “Medical Laboratory Joint Innovation Platform” – the group has deeply cooperated with Fudan University, the First Affiliated Hospital of Sun Yatsen University, and many other universities and top tier medical institutions to continuously advance the translational research and clinical optimization of mNGS technology. Leveraging accumulated large sample data, YunKang constantly iterates its bioinformatics analysis algorithms to enhance detection accuracy and interpretation efficiency.

In the future, YunKang will continue to increase investment in technology R&D, deepen its commitment to the field of metagenomic diagnosis of infectious pathogens, promote the widespread application of mNGS technology in more clinical scenarios, and provide key decisionmaking evidence for solving more clinically challenging infectious cases.